701. Receipt and survival outcomes by age following second-line therapy for metastatic CRC (mCRC): Analysis of 5,289 patients from the ARCAD Clinical Trials Program
- Author
-
Mace L. Rothenberg, Paulo M. Hoff, William S. Harmsen, Stuart M. Lichtman, Alberto Sobrero, Qian Shi, Arnold Dirk, Nadine Jackson McCleary, Richard M. Goldberg, Miriam Koopman, Bruce J. Giantonio, Eric VanCutsem, Josep Tabernero, Henry C. Pitot, Matthew T. Seymour, Aimery de Gramont, Leonard B. Saltz, Alfredo Falcone, and Hans-Joachim hans-joachim Schmoll
- Subjects
Oncology ,Clinical trial ,Receipt ,Cancer Research ,medicine.medical_specialty ,Second-line therapy ,business.industry ,Internal medicine ,medicine ,business - Abstract
6 Background: Rates and survival outcomes for second-line therapy for mCRC for OA vs. YA are poorly understood. Methods: Pts with available subsequent treatment data after progression from 10 1st line trials were included. Associations between key clinical/disease characteristics, time to initial progression (TTiP) and rate of receipt of second-line therapy were evaluated. Time to progression (TTP) and overall survival (OS) were compared between OA and YA who were enrolled on second-line trials by Cox regression, adjusting for age, sex, ECOG PS, number of metastatic sites, presence of metastasis in lung/liver/peritoneum. Results: OA comprised 16.4% of first-line trials. OA and ECOG PS >0 were less likely to receive second-line therapy than YA. Odds of receiving second-line therapy decreased by 11% for each additional decade of life in multivariate analysis (p=0.0117). OA enrolled in second-line trials experience similar mTTP and mOS as YA (5.1 vs. 5.2mos; 11.6 vs 12.4mos, respectively). Conclusions: OA are less likely to receive 2nd line therapy for mCRC. We did not observe a statistical difference in survival outcomes for OA vs. YA following second-line therapy. Further study is needed to examine unmeasured factors, including comorbidity and functional status given observed inferior outcomes among adults with ECOG PS >0, and consideration given to inclusion of geriatric assessment to select OA likely to benefit from 2nd line therapy for mCRC. [Table: see text]